Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-tzmfd Total loading time: 0 Render date: 2025-05-04T09:48:17.174Z Has data issue: false hasContentIssue false

25 - How to assess risk: prospective studies and calculations

from Section 3 - Surveillance, risk and regulation

Published online by Cambridge University Press:  12 January 2010

By
Kate Soldan  and
Katy Davison
Edited by
John A. J. Barbara ,
Fiona A. M. Regan  and
Marcela Contreras
Kate Soldan
Affiliation:
Epidemiologist, HIV/STI Department, Health Protection Agency Centre for Infections Colindale, London, UK
Katy Davison
Affiliation:
Scientist (Epidemiology), Immunization Department, Health Protection Agency Centre for Infections Colindale, London, UK
John A. J. Barbara
Affiliation:
University of the West of England, Bristol
Fiona A. M. Regan
Affiliation:
HNSBT and Hammersmith Hospitals NHS Trust, London
Marcela Contreras
Affiliation:
University of the West of England, Bristol
Get access

Summary

Introduction

Assessing, or quantifying, the risk of transfusion-transmission of infection can be attempted by several approaches, each having different costs, advantages and limitations. Surveillance systems, as described in Chapter 21, can monitor diagnosed transfusion-transmitted infections. However, several factors common to transfusion-transmitted infections, and to transfusion recipients, are likely to contribute to a lack of clinically apparent symptoms and therefore to under-diagnosis of infections. For example, other therapies may negate or modify symptoms. Many transfusion recipients are receiving antibiotic drugs and are therefore less likely to suffer observable consequences from bacterial infections. Transfusion recipients may be sick or injured, are often elderly, and have high mortality from other causes. Furthermore, the recipients who receive relatively large numbers of transfusions, and are therefore at the highest risk of transfusion-transmitted infections, have the highest comorbidity and mortality rates. Long pre-symptomatic periods are common for persistent blood-borne virus infections and occurrence of disease may be far removed in time from the transfusion-exposure. This period may be shortened by a relatively large dose of the infectious agent, and in recipients who are older, already ill or immunocompromised. Such characteristics are common amongst transfusion recipients, but even so, transfusion may be overlooked as a possible route of infection due to some delay in diagnosis. For some infections (for example hepatitis A and parvovirus B19), naturally acquired immunity may be quite high – especially in older age groups – meaning that transmission of infection may be considerably less frequent than the number of infectious units of blood transfused.

Type
Chapter
Information
Transfusion Microbiology , pp. 329 - 340
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Alvarez, M., González, R., Hernández, J. M., et al. (2005) Residual risk of transfusion-transmitted viral infections in Spain, 1997–2002, and impact of nucleic acid testing. Euro Surveill, 10(2), 20–2.Google Scholar
Alvarez, M., Oyonarte, S., Rodriguez, P. M., et al. (2002) Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion, 42, 994–8.CrossRefGoogle ScholarPubMed
Armitage, P. and Colton, T. (editors-in-chief) (1998) Binomial confidence intervals when no events are observed. Encyclopedia of Biostatistics, 1, 358.Google Scholar
Atrah, H. I., Ala, F. A., Ahmed, M. M., et al. (1996) Unexplained hepatitis C virus antibody seroconversion in established blood donors. Transfusion, 36, 339–43.CrossRefGoogle ScholarPubMed
Barrera, J. M., Francis, B., Ercilla, G., et al. (1995) Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang, 68, 15–18 (and personal communication with authors).CrossRefGoogle ScholarPubMed
Brennan, M. T., Hewitt, P. E., Moore, C., et al. (1995) Confidential unit exclusion: the North London Blood Centre's experience. Transfus Med, 5, 51–6.CrossRefGoogle ScholarPubMed
Brookmeyer, R. and Gail, M. H. (1994) Epidemiology: a Quantitative Approach. Buckingham, Open University Press. Oxford, UK.Google Scholar
Busch, M. P., Lee, L. L., Satten, G. A., et al. (1995) Time course of detection of viral and serological markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion, 35, 91–7.CrossRefGoogle Scholar
Courouce, A. M. and Pillonel, J. (1996) Estimation du risque de transmission des virus des hepatitis B et C, et des retrovirus par transfusion de derives sanguins labiles. Bulletin Epidemiologique Hebdomadaire, 11, 54–5.Google Scholar
Crawford, R. J., Mitchell, R., Burnett, A. K., et al. (1987) Who may give blood?BMJ, 294, 572.CrossRefGoogle ScholarPubMed
Cumming, P. D., Wallace, E. L., Schorr, J. B., et al. (1989) Exposure of patients to HIV through the transfusion of blood components that test antibody negative. N Eng J Med, 321, 941–6.CrossRefGoogle ScholarPubMed
Dax, E. M., Healey, D. S. and Crofts, N. (1992) Low risk of HIV-1 infection from blood donation: a test-based estimate (letter). Med J Aust, 157, 69.Google Scholar
Dodd, R. Y., Notari, E. P. and Stramer, S. L. (2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42, 975–9.CrossRefGoogle ScholarPubMed
Durand, F. and Baeuplet, A. (2000) Evidence of hepatitis C virus viraemia without detectable antibody to hepatitis C virus in a blood donor (letter). Ann Intern Med, 133(1), 74.CrossRefGoogle Scholar
Germain, M., Remis, R. S. and Delage, G. (2003) The risks and benefits of accepting men who have had sex with men as blood donors. Transfusion, 43, 25–33.CrossRefGoogle ScholarPubMed
Gluck, D., Kubanek, B., Maurer, C., et al. (1998) Seroconversion of HIV, HCV, and HBV in blood donors in 1996 – risk of virus transmission by blood products in Germany. Infusion Therapy and Transfusion Medicine, 25, 82–4.Google Scholar
Glynn, S. A., Kleinman, S. H., Wright, D. J., et al. (2002) International application of the incidence rate/window period model. Transfusion, 42, 966–72.CrossRefGoogle ScholarPubMed
Gurtler, L. (1998) The impact of HIV subtypes and variants on the stability of HIV screening assays. Infusion Therapy and Transfusion Medicine, 25(2), 9.Google Scholar
Hewitt, P. E., Kendall, B. and Barbara, J. A. J. (1997) Hepatitis A transmitted by red cell transfusion. Transfus Med, 7(Suppl. 1), 48 (abstract).Google Scholar
Hickman, M. and Mortimer, J. Y. (1988) Donor screening for HIV: how many false negatives? (letter). Lancet, 28, 1221.CrossRefGoogle Scholar
Hoofnagle, J. H. and Schaffer, D. F. (1986) Serological markers of hepatitis B virus infection (review). Seminars in Liver Disease, 6(1), 1–10.CrossRefGoogle Scholar
Hoofnagle, J. H., Seeff, L. B., Buskell-Bales, Z., et al. (1978) Serological responses in HB. In Viral Hepatitis: a Contemporary Assessment of Aetiology, Epidemiology, Pathogenesis and Prevention, eds. Vyas, G. N., Cohen, S. N. and Schmid, R., pp. 219–42. Philadelphia, Franklin Institute Press.Google Scholar
Janssen, R. S., Satten, G. A., Stramer, S. L., et al. (1998) New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA, 280(1), 42–8.CrossRefGoogle ScholarPubMed
Jongerius, J. M., Wester, M., Cuypers, H. T. M., et al. (1998) New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion, 38, 56.CrossRefGoogle Scholar
Kitayaporn, D., Kaewkungwal, J., Bejrachandra, S., et al. (1996) Estimated rate of HIV-1 infectious but seronegative blood donations in Bangkok, Thailand. AIDS, 10, 1157–62.Google ScholarPubMed
Koerner, K., Cardoso, M., Dengler, T., et al. (1998) Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang. 74(4), 213–6.CrossRefGoogle ScholarPubMed
Korelitz, J. J., Busch, M. P., Kleinman, S. H., et al. (1997) A method for estimating hepatitis B virus incidence rates in volunteer blood donors. Transfusion, 37, 634–40.CrossRefGoogle ScholarPubMed
Kothe, D., Byers, R. H., Caudill, S. P., et al. (2003) Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr, 33(5), 15 Aug 625–34.CrossRefGoogle ScholarPubMed
Lackritz, E. M., Satten, G. A., Aberle-Grasse, J., et al. (1995) Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Eng J Med, 333, 1721–5.CrossRefGoogle ScholarPubMed
Linden, J. V. (1994) Error contributes to the risk of transmissible disease. Transfusion, 34, 1016.CrossRefGoogle ScholarPubMed
Linden, J. V. and Kaplan, H. S. (1994) Transfusion errors: causes and effects. Transfus Med Rev, 8, 169–83.CrossRefGoogle ScholarPubMed
Martlew, V. J., Carey, P., William, C. Y., et al. (2000) Post-transfusion HIV infection despite donor screening: a report of three cases. J Hosp Infect, 44(2), 93–7.CrossRefGoogle ScholarPubMed
McFarland, W., Busch, M. P., Kellogg, T. A., et al. (1999) Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counselling and testing sites in San Francisco. J Acquir Immune Defic Syndr, 22(5), 484–9.CrossRefGoogle ScholarPubMed
Mimms, L. T., Mosley, J. W., Hollinger, F. B., et al. (1993) Effect of concurrent acute infection with hepatitis C on acute hepatitis B virus infection. BMJ, 307, 1095–7.CrossRefGoogle ScholarPubMed
Muller-Breitkreutz, K. (2000) Results of viral marker screening of unpaid blood donations in 1997 and probability of window period donations. Vox Sang, 78, 149–57.CrossRefGoogle ScholarPubMed
Medical Devices Agency Report (1995). PHLS Kit Evaluation Group, Hepatitis and Retrovirus Laboratory, Medical Devices Agency.
Niederhauser, C., Schneider, P., Fopp, M., et al. (2005) Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003. Euro Surveill, 10(2), 14–6.CrossRefGoogle ScholarPubMed
Offergeld, R., Faensen, D., Ritter, S., et al. (2005) Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000–2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill, 10(2), 8–11.CrossRefGoogle ScholarPubMed
Pillonel, J. and Laperche, S. (2005) Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill, 10(2), 5–8.CrossRefGoogle Scholar
Pillonel, J., Laperche, S., Saura, C., et al. (2002) Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion, 42, 980–8.CrossRefGoogle ScholarPubMed
Regan, F. A. M., Hewitt, P. E., Barbara, J. A. J., et al. (2000) Prospective investigation of transfusion-transmitted infection in recipients of over 20 000 units of blood. BMJ, 320, 403–6.CrossRefGoogle ScholarPubMed
Look-back Coordinators, Transfusion transmission of HCV infection prior to anti-HCV testing of blood donations in England: results of the national HCV lookback programme. Transfusion, 2001 (in press).
Riggert, J., Schwartz, D. W., Uy, A., et al. (1996) Risk of hepatitis C virus (HCV) transmission by anti-HCV-negative blood components in Austria and Germany. Ann Hematol, 72(1), 35–9.CrossRefGoogle ScholarPubMed
Schreiber, G. B., Busch, M. P. and Kleinman, S. H. (1996) The risk of transfusion-transmitted viral infections. New England Journal Medicine, 334, 1685–90.CrossRefGoogle ScholarPubMed
Schreiber, G. B., Glynn, S. A., Satten, G. A., et al. (2002) HIV seroconverting donors delay their return: screening test implications. Transfusion, 42(4), 414–21.CrossRefGoogle ScholarPubMed
Sitas, F., Fleming, A. F. and Morris, J. (1994) Residual risk of transmission of HIV through blood transfusion in South Africa. S Afr Med J, 84(3), 142–4.Google ScholarPubMed
Soldan, K. and Sinka, K. (2003a) Evaluation of the de-selection of men who have had sex with men from blood donation in England. Vox Sang. 84(4), 265–73.CrossRefGoogle Scholar
Soldan, K., Barbara, J. A. J., Ramsay, M., et al. (2003b) Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993–2001. Vox Sang, 84(4), 274–86.CrossRefGoogle Scholar
Soldan, K., Barbara, J. A. J. and Heptonstall, J. (1998) Incidence of seroconversion to positivity for hepatitis C antibody in repeat blood donors in England, 1993–1995. BMJ, 316, 1413–7.CrossRefGoogle Scholar
Soldan, K., Davison, K. and Dow, B. (2005) Estimates of the frequency of HBV, HCV and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill, 10(2), 17–9.CrossRefGoogle ScholarPubMed
Soldan, K.Ramsay, M. and Collins, M. (1999) Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991–1997: review of database. BMJ, 318, 95.CrossRefGoogle Scholar
Schwartz, D. W., Simson, G., Baumgarten, K., et al. (1995) Risk of human immunodeficiency virus (HIV) transmission by anti-HIV-negative blood components in Germany and Austria. Ann Hematol, 70(4), 209–13.CrossRefGoogle ScholarPubMed
Velati, C., Fomiatti, L., Baruffi, L., et al. (2005) Gruppo Italiano per lo Studio delle Malattie Trasmissibili con la Trasfusione. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001–2003). Euro Surveill, 10(2), 12–4.CrossRefGoogle Scholar
Velati, C., Romano, L., Baruffi, L., et al. (2002) Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion, 42, 989–93.CrossRefGoogle ScholarPubMed
Ward, J. W., Holmberg, S. D., Allen, J. R., et al. (1988) Transmission of HIV by blood transfusions screened as negative for HIV antibody. N Eng J Med, 318, 473–8.CrossRefGoogle ScholarPubMed
Whyte, G. S. and Savoia, H. F. (1997) The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria. Med J Australia, 166, 584–6.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×